Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Serina Therapeutics, Inc.AGE · Entity 9581 | Director | February 02, 2022 | February 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Serina Therapeutics, Inc.
Report date February 02, 2022 · Filed February 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2032-02-01 | Direct | 65,000 |
Reported balance
After 2022-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-02 · Grant · Acquired 65,000 · Balance 65,000 F1: Options will vest and become exercisable in four equal quarterly installments on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022, provided that the grantee remains a director on the last day of the applicable calendar quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: Options will vest and become exercisable in four equal quarterly installments on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022, provided that the grantee remains a director on the last day of the applicable calendar quarter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2022 Filed Feb 4, 2022 21:50 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantOption to Purchase Common Stock · Derivative | 65,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001209191-22-007213 · doc4.xml · derivative · entry 1 Hackett Joanne M. · CIK 0001905966 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: Options will vest and become exercisable in four equal quarterly installments on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022, provided that the grantee remains a director on the last day of the applicable calendar quarter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.